Citations

Clear

9383 citation(s) found for "Thomas, PS".

Congenital myasthenic syndrome: is it time for a name change to genetic myasthenic syndrome?
Ramdas, Sithara , Dong, Yin Yao , Munot, P., Benito, Daniel Natera de, Osorio, A Nascimento, Maggi, Lorenzo, Bönnemann, C, McAnally, Meghan , Schara-Schmidt, Ulrike, Marina, Adela Della , Kostera-Pruszczyk, Anna, Milone, Margherita , Evoli, Amelia , Jungbluth, Heinz, Lochmüller, H., Beeson, D. J., Reddel, Stephen SW, Palace, Jacqueline, Palace, Jacqueline , Jungbluth, Heinz , Beeson, David , Palace, Jacqueline , Munot, Pinki , Benito, Daniel Natera‐de , Maggi, Lorenzo , Bönnemann, Carsten G. , Schara, Ulrike , Kostera‐Pruszczyk, Anna , Reddel, Stephen

Mayo Clinic

Brain | February 2, 2026 | Volume: 149 | Issue: 6 | Pages: 1816-1818

10.1093/brain/awag035 | PMID 41630153 Get It

Ramdas et al. propose renaming ‘congenital myasthenic syndrome’ as ‘genetic myasthenic syndrome’. They argue that ‘congenital’ misleadingly implies neonatal onset, which may contribute to delayed diagnosis and management, and that revised nomenclature could improve patient outcomes.
Association of CDKN2A/B and MTAP deletions in adult-type diffuse gliomas
Ebner, Blake A. , Ida, Cristiane M. , Jenkins, Robert B, Mendoza, Cinthya J Zepeda, Giannini, C., Trejo-Lopez, Jorge, Raghunathan, Aditya, Jenkins, RB , Zepeda Mendoza, Cinthya J, Trejo-Lopez, Jorge A, Raghunathan, Aditya , Ida, Cristiane M , Kollmeyer, Thomas M. , Jenkins, Robert B. , Zepeda‐Mendoza, Cinthya , Trejo‐Lopez, Jorge , Raghunathan, Aditya

Mayo Clinic

Journal of Neuropathology & Experimental Neurology | January 31, 2026 | Volume: 85 | Issue: 6 | Pages: 551-560

10.1093/jnen/nlag007 | PMID 41802222 Get It

Abstract In adult-type diffuse gliomas CDKN2A and/or CDKN2B (CDKN2A/B) deletions often co-occur with deletion of MTAP, suggesting that MTAP immunohistochemistry (IHC) may be a surrogate marker of CDKN2A/B status. However, the association between CDKN2A/B and MTAP deletion at the genomic level remains unknown. We assessed CDKN2A/B and MTAP deletions by chromosomal microarray in 333 adult-type diffuse gliomas and performed MTAP IHC on a subset (n = 63). CDKN2A/B and MTAP deletions were detected in 216 and 215 cases, respectively, and were concurrent in 99.5% (215/216). While most tumors with CDKN2A/B homozygous deletion (n = 148) showed concurrent MTAP homozygous deletion (108/148; 73.0%), a subset harbored MTAP heterozygous deletion (39/148; 26.4%). By analyzing the size of the chromosomal alterations, we demonstrate that initial large chromosomal 9p losses result in concurrent heterozygous deletion of CDKN2A/B and MTAP whereas smaller “second hit” deletions leading to homozygous CDKN2A/B deletion do not always encompass the MTAP locus. Discordant CDKN2A/B and MTAP tumors affect the association between MTAP IHC and copy number status of MTAP and CDKN2A/B. These findings suggest that adult-type diffuse gliomas, regardless of IDH status, follow a stereotypic pathway involving concurrent CDKN2A/B and MTAP heterozygous deletion but may diverge for CDKN2A/B and MTAP homozygous deletion.
Long‐term amyloid PET and MRI outcomes in a menopausal hormone therapy trial
Kantarci, Kejal, Tosakulwong, Nirubol , Fought, Angela J. , Schwarz, Christopher G, Kendall-Thomas, June, Min, Paul H., Lowe, VJ, Jack, Clifford R, Kapoor, Ekta, Fields, Julie A. , Bailey, Kent R., James, Taryn T. , Faubion, Laura L. , Ra, Lobo, Manson, JoAnn E, Pal, Lubna, Hammers, Dustin B, Malek-Ahmadi, Michael, Cedars, Marcelle I., Naftolin, Frederick N, Santoro, N., Miller, V. M., Harman, Sherman, Gleason, Carey E, Min, Hoon‐Ki , Min, Paul, Min, Hoon-Ki Paul , Kantarci, Kejal , Kara, Firat , Schwarz, Christopher G. , Senjem, Matthew L. , Kendall‐Thomas, June, Jack, Clifford R. , Kapoor, Ekta , Manson, JoAnn E. , Pal, Lubna , Hammers, Dustin B , Brinton, Eliot A. , Malek‐Ahmadi, Michael , Cedars, Marcelle I. , Naftolin, Frederick , Harman, S. Mitchell , Dowling, N. Maritza , Gleason, Carey E.

Mayo Clinic

Alzheimer's & Dementia | January 31, 2026 | Volume: 22 | Issue: 2 | Pages: No page available

10.1002/alz.71067 | PMID 41618732 Get It

Abstract INTRODUCTION Associations of short‐term use of menopausal hormone therapy (mHT) with Alzheimer's disease (AD) and structural magnetic resonance imaging (MRI) biomarkers were investigated 10 years after an mHT trial. METHODS Recently menopausal women with good cardiovascular health were randomized to oral conjugated equine estrogens (oCEE) or transdermal 17β‐estradiol (tE2) and micronized progesterone, or placebo for 4 years. Amyloid beta (Aβ) on positron emission tomography, hippocampal atrophy, and dorsolateral prefrontal cortex thickness on MRI were assessed 10 years after completion of the mHT trial ( n = 266). RESULTS Aβ and structural MRI biomarkers were not different in the oCEE and tE2 groups compared to placebo. Apolipoprotein E ε4 status did not modify the findings. DISCUSSION There was no evidence of adverse effects or benefits associated with 4 years of use of oral or transdermal mHT on Aβ and structural MRI biomarkers in relatively healthy women, 10 years after mHT. Findings support the long‐term safety of short‐term use of mHT on brain health. CLINICAL TRIALS REGISTRATION NCT00154180 Kronos Early Estrogen Prevention Study (KEEPS) Highlights There were no menopausal hormone therapy–related adverse effects or benefits on amyloid beta and magnetic resonance imaging biomarkers in the long term. Apolipoprotein E ε4 carrier status did not modify these findings. Findings align with neutral cognitive and cerebrovascular outcomes in this cohort.
Recommendations for Advanced Practice Provider Postgraduate Training Programs in the United States: A Work Product of the Advanced Practice Provider Postgraduate Training Task Force of the Society of Critical Care Medicine
Ricker, Melissa, Abide, Aimee, Bakshi, Vishal, Bane, Tina, Bhullar, Simrit K., Byrd, Cindy , Fuller, Todd E., Gunville, Cameron, Hogan, Brett , Nugent, Katherine Lyn, Pandya, Komal , Peacock, Sarah, Pisa, Michael, Meissen, Heather H., McLaughlin, Diane , Boling, Bryan , Farley, Thomas, Newman, Christopher, Nugent, Katherine Lyn, Peacock, Sarah, Meissen, Heather

Mayo Clinic

Critical Care Medicine | January 30, 2026 | Volume: 54 | Issue: 4 | Pages: 825-835

10.1097/ccm.0000000000007061 | PMID 41615242 Get It

OBJECTIVES: The overall goal of this work is to discuss the various topics associated with critical care advanced practice provider (APP) postgraduate training programs and provide resources for new, developing and existing programs. DESIGN: Three rounds of voting until consensus achieved. SETTING: Electronic surveys, followed by virtual meeting. SUBJECTS: Critical care APPs, physicians, a pharmacist, and a nurse were also included to ensure multidisciplinary representation. All subjects resided and practiced in the United States with a history of education scholarship or post-graduate training leadership. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: The workgroup included 14 APPs (ten nurse practitioners and four physician associates), three physicians, one pharmacist, and one registered nurse from 14 institutions across the United States. The workgroup identified six areas of concentration: administration, audience, program structure, curriculum, procedural competence, and accreditation. A survey was generated and employed in three rounds. The first two rounds of voting were completed anonymously, the third round was completed as a live meeting until consensus recommendations, defined as 75% agreement or more, were achieved. CONCLUSIONS: Expert consensus was used to generate consensus recommendations for critical care postgraduate training programs based upon 3 rounds of voting.
Relationship between age and severity of cognitive impairment at diagnosis for early‐onset and late‐onset Alzheimer's disease: Comparison of LEADS and ADNI
Hammers, Dustin B., Eloyan, Ani, Thangarajah, Maryanne, Taurone, Alexander, Gao, Sujuan, Beckett, Laurel, Kirby, Kala, Dage, Jeffrey L., Nudelman, Kelly, Aisen, Paul, Reman, Rema, Vemuri, Prashanthi, Joie, Renaud La, Touroutoglou, Alexandra, Atri, Alireza, Clark, David, Day, Gregory S., Duara, Ranjan, Graff‐Radford, Neill R., Honig, Lawrence S., Jones, D., Masdeu, Joseph C. , Mendez, Mario F., Womack, Kyle, Musiek, Erik, Onyike, Chiadi U., Riddle, Meghan, Grant, Ian, Rogalski, Emily, Johnson, Erik C. B., Salloway, Steven, Sha, Sharon J. , Turner, Raymond Scott, Wingo, Thomas S., Wolk, David A., Carrillo, Marı́a C., Dickerson, Bradford C., Rabinovici, Gil D., Apostolova, Liana G., Initiative, for the Alzheimer's Disease Neuroimaging, Carrillo, María C. , Rabinovici, Gil D. , Joie, Renaud La , Day, Gregory S. , Day, Gregory S , La Joie, Renaud , Rabinovici, Gil D , Hammers, Dustin B , Eloyan, Ani , Taurone, Alexander, Gao, Sujuan , Beckett, Laurel , Dage, Jeffrey L. , Nudelman, Kelly , Aisen, Paul , Reman, Rema, Vemuri, Prashanthi , Touroutoglou, Alexandra , Atri, Alireza , Clark, David, Duara, Ranjan , Graff‐Radford, Neill R. , Honig, Lawrence S. , Jones, David T. , Masdeu, Joseph C , Mendez, Mario F. , Musiek, Erik , Onyike, Chiadi U. , Riddle, Meghan , Johnson, Erik C. B. , Salloway, Steve , Turner, Raymond Scott , Wolk, David A. , Dickerson, Bradford Clark , Apostolova, Liana G. , Initiative, for the Alzheimer’s Disease Neuroimaging

Mayo Clinic

Alzheimer's & Dementia | January 30, 2026 | Volume: 22 | Issue: 2 | Pages: No page available

10.1002/alz.71160 | PMID 41614286 Get It

INTRODUCTION Recent work has identified unique cognitive profiles for early‐onset Alzheimer's disease (EOAD) relative to late‐onset Alzheimer's disease (LOAD), however, examination has been limited in determining whether the association between age and cognitive severity at presentation also differs across conditions. METHODS A series of linear spline regression models was conducted across baseline cognitive data from 325 EOAD and 314 LOAD participants, after accounting for education, sex, and apolipoprotein ε4 status. RESULTS Significant differences existed in the relationship between baseline age and cognitive performance between EOAD and LOAD samples for Processing Speed/Attention, Executive Functioning, and Episodic Immediate Memory. Younger participants from both EOAD and LOAD groups performed disproportionately worse on non‐amnestic cognitive domains, with this occurring to a greater extent in EOAD than LOAD. DISCUSSION In the age of disease‐modifying treatments, results highlight the importance of assessing for cognitive declines in individuals starting much earlier than age 65. Highlights Early‐onset Alzheimer's disease (EOAD) and late‐onset Alzheimer's disease (LOAD) participants each displayed cognitive impairments relative to same‐aged peers across most domains. Both groups displayed positive relationships between impairment among non‐amnestic cognitive domains and baseline age. This relationship displayed a significantly greater effect in EOAD than LOAD, with domains of Processing Speed/Attention and Executive Functioning skills being the most pronounced. Of those participants developing AD, age displayed a disproportionate impact on their symptom onset.
Multicenter Evaluation of Myocardial Flow Reserve as a Prognostic Marker for Mortality in 13 N-Ammonia PET Myocardial Perfusion Imaging
Ramirez, Giselle, Builoff, Valerie , Miller, R., Lemley, Mark , Carvajal-Juarez, Isabel, Alexanderson, Erick, Rosamond, Thomas, Song, Na , Travin, Mark I. , Slipczuk, Leandro, Wopperer, Samuel, Carli, Marcelo F. Di, Chareonthaitawee, Panithaya, Slomka, Piotr J, Slipczuk, Leandro , Miller, Robert J.H. , Carvajal-Juarez, Isabel , Miller, Robert J H , Carvajal-Juarez, Isabel , Slipczuk, Leandro , Einstein, Andrew Jeffrey , Wopperer, Samuel B., Di Carli, Marcelo F , Chareonthaitawee, Panithaya , Slomka, Piotr J , Lemley, Mark , Alexanderson, Erick , Wopperer, Samuel, Carli, Marcelo F. Di , Chareonthaitawee, Panithaya

Mayo Clinic

Circulation: Cardiovascular Imaging | January 30, 2026 | Volume: 19 | Issue: 4 | Pages: No page available

10.1161/circimaging.125.018729 | PMID 41614241 Get It

BACKGROUND: Myocardial flow reserve (MFR), measured by positron emission tomography (PET) myocardial perfusion imaging, provides valuable information on epicardial coronary disease, diffuse atherosclerosis, and microvascular function. Despite its routine use, the prognostic efficacy of 13 N-ammonia PET MFR remains unconfirmed in larger multicenter cohorts of patients with suspected or known coronary artery disease. METHODS: We considered patients from 5 sites in the REFINE PET (Registry of Flow and Perfusion Imaging for Artificial Intelligence with PET) registry who underwent 13 N-ammonia PET myocardial perfusion imaging for coronary artery disease. Clinical and imaging data were collected at the time of myocardial perfusion imaging. MFR was quantified as the ratio of stress to rest myocardial blood flow, using QPET software (Cedars-Sinai Medical Center, Los Angeles, CA). The primary outcome was all-cause mortality. Survival analyses were performed using Kaplan-Meier and Cox regression models adjusted for clinical and imaging covariates. RESULTS: In total, 6277 patients were included (median age of 65 years, 56% male). Median follow-up time was 3.8 years. There were 1895 patients with MFR ≤2 and 4382 with MFR >2. Patients with MFR ≤2 had significantly higher mortality than those with MFR >2 (n=701 [37.0%] versus n=537 [12.3%], respectively; P <0.001). Annualized all-cause mortality rates by MFR and summed stress score ranged from 1.7 to 15.8. In multivariable analysis, MFR ≤2 was independently associated with increased all-cause mortality in the overall population (hazard ratio, 2.70 [95% CI, 2.41–3.03]; P <0.001), even among patients with no perfusion defects (hazard ratio, 2.36 [95% CI, 1.93–2.89]; P <0.001). Mortality risk decreased across increasing MFR deciles, ranging from hazard ratio, 2.73 (95% CI, 2.39–3.11) to hazard ratio, 0.35 (95% CI, 0.25–0.49). CONCLUSIONS: In this large multicenter cohort, MFR derived from 13 N-ammonia PET myocardial perfusion imaging is a strong, independent predictor of all-cause mortality, even in patients with normal perfusion. An MFR of ≤2 identifies elevated risk, while higher values are associated with improved survival. These findings support the routine integration of MFR to enhance risk stratification in patients with suspected or known coronary artery disease.
Steroidal vs. non-steroidal mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction: a propensity-matched multi-network nationwide cohort study
Almas, Talal , Shelig, Mohamed , Al-Hindawi, Ahmed, Akbar, Absam , Qureshi, Amal Naveed, Ismayl, Mahmoud, Reed, Joseph, Burahmah, Jasem, AlHamlan, Abdullah W, AlMojil, Khaled, Almukhaizeem, Abdullah, Rana, Mariam , Alansari, Ali, Ramani, Ravi , Sullivan, Claire, Simon, Daniel I. , O'Neill, Thomas Joseph, Reed, Joseph A, Simon, Daniel I , Al-Hindawi, Ahmed , Bansal, Kannu , Ismayl, Mahmoud , Alhamlan, Abdullah W., Alansari, Ali, Zacharias, Michael P, Desai, Nihar R.

Mayo Clinic

European Heart Journal - Quality of Care and Clinical Outcomes | January 29, 2026 | Volume: 12 | Issue: 5 | Pages: 718-730

10.1093/ehjqcco/qcag014 | PMID 41616082 Get It

Abstract Aims Heart failure (HF) continues to portend significant morbidity and mortality within the USA. Data regarding the efficacy of mineralocorticoid receptor antagonists (MRAs) in HF with preserved ejection fraction (HFpEF) remains unclear. Finerenone, a non-steroidal MRA, has demonstrated reduction in hospitalizations in this population. However, the comparative efficacy of different MRA classes in these patients remains elusive. Methods and results We conducted a retrospective observational cohort study using the TriNetX research network. We applied 1:1 propensity score matching (PSM) to compare patients with HFpEF initiated on finerenone vs. spironolactone. We examined 1-year risks of HF exacerbation, acute kidney injury (AKI), electrolyte derangements, and cardiovascular outcomes. We identified 254,417 patients with HFpEF and MRA use. After PSM, each cohort contained 491 patients. Analysis revealed that finerenone use was associated with a significantly lower risk of HF exacerbation (hazard ratio [HR] = 0.63 [95% confidence interval [CI]: 0.54, 0.74], P &lt; 0.001), all-cause mortality (HR = 0.38 [95% CI: 0.23, 0.64], P &lt; 0.001), and hypokalaemia (HR = 0.58 [95% CI: 0.40, 0.85], P = 0.001). The aforementioned results, along with a reduction in AKI risk, were statistically significant after stratified subgroup analysis by diabetes mellitus and chronic kidney disease. Conclusion In this large real-world HFpEF cohort, finerenone use was associated with lower risks of HF exacerbation and all-cause mortality compared with spironolactone. These observational findings are hypothesis-generating and warrant confirmation in randomized trials.
Abstract DP233: Plasma Biomarkers of Alzheimer’s Disease, White Matter Hyperintensities, and Dementia Risk: The Atherosclerosis Risk in Communities Study
Kinyanjui, Elise, Groechel, Renee, Morrill, Valerie, Lutsey, Pamela, Walker, Keenan, Sullivan, Kevin, Sharrett, A, Knopman, David, Coresh, Joe, Mosley, Thomas, Palta, Priya, Gottesman, Rebecca, Groechel, Renée C. , Morrill, Valerie, Lutsey, Pamela L. , Sharrett, A. Richey, Knopman, David, Gottesman, Rebecca

Mayo Clinic

Stroke | January 29, 2026 | Volume: 57 | Issue: Suppl_1 | Pages: No page available

10.1161/str.57.suppl_1.dp233 Get It

Introduction: Plasma biomarkers of Alzheimer’s disease (AD), including amyloid-β (Aβ42/Aβ40), phosphorylated tau (p-tau181), neurofilament light (NfL), and glial fibrillary acidic protein (GFAP) have shown strong reliability in predicting dementia risk. White matter hyperintensities (WMH) represent a major vascular contributor to dementia. We investigated how plasma biomarkers of AD interact with WMH on MRI to influence incident dementia risk. Methods: We included dementia-free participants from the Atherosclerosis Risk in Communities (ARIC) Study who underwent MRI and plasma biomarker assessment at Visit 5 (2011–2013). WMH was quantified and considered continuously (log-transformed and standardized), and in tertiles. Plasma biomarkers were log-base-2-transformed. Cox proportional hazards models were used to estimate dementia risk over 10 years associated with plasma biomarkers and WMH, independently and multiplicatively. Models were adjusted for demographic variables (age, sex, race, and education), vascular risk factors (hypertension, diabetes, smoking status, body mass index, and estimated glomerular filtration rate), and APOE ε4 status. Results: Among 1,538 participants (aged 67- 90 years, 29% Black), 30% ( N = 462) developed dementia over the 10-year follow-up period. For every doubling of plasma Aβ42/Aβ40 , indicating lower amyloid burden, dementia risk decreased, while doubling of p-tau 181 , NfL, and GFAP were each associated with increased dementia risk, in separate models; each of these associations was independent of WMH (Table 1). Additionally, dementia risk increased per SD increase in WMH, independent of each plasma biomarker. Although no multiplicative interaction terms reached statistical significance (p<0.05), there was suggestive evidence that Aβ42/Aβ40 and GFAP have smaller effect sizes on dementia risk in subgroups at the highest WMH tertile (p-interactions<0.10; see Table 2). Discussion: Plasma biomarkers and WMH independently predict dementia risk over 10 years, though there remained limited evidence of multiplicative effects. Plasma biomarkers may be less important for dementia risk in individuals who also have extensive WMH. These findings emphasize the importance of incorporating both AD-specific plasma markers as well as indicators of cerebral small vessel disease, such as WMH, into dementia risk profiling.
Abstract DP096: Associations of Late-life Depression with Neuroimaging Markers of Cerebrovascular and Neurodegenerative Disease
Kanetkar, Sylee , Morrill, Valerie, Fornage, Myriam, Jack, Clifford, Knopman, David, Mosley, Thomas, Schneider, Andrea, Fracica, Elizabeth , Gottesman, Rebecca, Schneider, Andrea , Morrill, Valerie, Fornage, Myriam , Jack, Clifford, Knopman, David, Schneider, Andrea, Gottesman, Rebecca

Mayo Clinic

Stroke | January 29, 2026 | Volume: 57 | Issue: Suppl_1 | Pages: No page available

10.1161/str.57.suppl_1.dp096 Get It

Objective: Epidemiological data have suggested that late-life depression (LLD) occurs as a consequence of cerebrovascular and neurodegenerative disorders, but there is also some evidence suggesting that the relationship may occur in the other direction, namely that LLD may be a risk factor for cerebrovascular and neurodegenerative disorders. However, the neurobiological basis of these associations remain unclear. This study investigated the associations of LLD with markers of cerebrovascular pathology, brain volumes, and cortical thickness from 3-Tesla brain magnetic resonance imaging (MRI). Methods: Participants from the Atherosclerosis Risk in Communities Study received brain MRI scans in late-life (ages 67-90). The following neuroimaging outcomes were assessed: cortical infarcts, lacunar infarcts, any microhemorrhages, lobar microhemorrhages, subcortical microhemorrhages, white matter hyperintensity volume, total and regional brain volumes (z-scores), and total average and regional cortical thickness (z-scores). At the same visit, LLD was evaluated with the 11-item Center for Epidemiological Studies Depression Scale (CES-D) and defined as CES-D score≥9. Associations between LLD and neuroimaging outcomes were examined using logistic and linear regression models, and were adjusted for age, race-center, sex, education level, vascular risk factors, stroke, cognitive status, APOE e4 carrier status, and total intracranial volume when assessing volumes. Results: Among 1,857 participants, the median age was 76 years, 59.5% were female, 28.3% were Black, and 6.8% had LLD. LLD was not associated with infarcts or microhemorrhages. There was no evidence of an association between LLD and total white matter hyperintensity volume or total average cortical thickness. However, LLD was independently associated with smaller volume (SD) of the rostral anterior cingulate (b 1 : -0.18; 95% CI: -0.33, -0.04) and greater cortical thickness (SD) in the medial orbitofrontal cortex (b 1 : 0.19; 95% CI: 0.01, 0.38), though effect sizes were small and did not survive correction for multiple comparisons. Conclusion: Findings from this study suggest LLD is not cross-sectionally associated with neuroimaging markers of cerebrovascular disease. While LLD may be linked to subtle volume and cortical thickness changes in specific regions of interest, future longitudinal research is warranted to validate and clarify these associations and explore their potentially bidirectional relationship.
Abstract DP084: Pre-Stroke Cognitive Impairment is Associated with an Elevated Risk of Incident Stroke: The ARIC-Neurocognitive Study (ARIC-NCS)
Ashley, Crystal, Morrill, Valerie, Mosley, Thomas, Knopman, David, Gottesman, Rebecca, Morrill, Valerie, Johansen, Michelle C. , Knopman, David, Koton, Silvia , Gottesman, Rebecca

Mayo Clinic

Stroke | January 29, 2026 | Volume: 57 | Issue: Suppl_1 | Pages: No page available

10.1161/str.57.suppl_1.dp084 Get It

Background: Stroke is a leading cause of death and disability despite advances in risk factor management. Many risk factors for stroke have also been implicated as risk factors for mild cognitive impairment (MCI) and dementia. Given these shared risk factors, cognitive impairment (CI) may represent an accumulation of neurological injury that is associated with an elevated risk of stroke. In ARIC-NCS, we aimed to 1) understand the independent relationship between pre-stroke CI (MCI or Dementia) and incident stroke; 2) explore mortality differences in stroke patients with vs without pre-stroke CI; and 3) evaluate modifiers of these relationships. Methods: 5434 stroke-free participants were evaluated for cognitive status at an in-person visit in 2011-13 (visit 5; ages 66-90), based on cognitive testing and informant interviews. Incident definite or probable strokes (ischemic or hemorrhagic) from visit 5 through 2022 were identified via ongoing surveillance (semi-annual telephone calls, with expert classification). Using Cox proportional hazards regression models adjusted for demographics and vascular risk factors, we evaluated associations between CI (MCI or dementia) and incident stroke, and between CI and death among individuals with stroke. Finally, we tested effect modification by age at visit 5, sex, education, and race, via stratified models and formal interaction terms. Results: Compared to those without CI, individuals with CI (23%) were older (77 vs 75 years, p<0.001), and more frequently male (48% vs 40%). Over 10+ years, CI was independently associated with an increased risk of incident stroke (HR:1.52, 95% CI:1.18-1.96). Among individuals with stroke, risk of death was also higher in CI vs non-CI patients (HR 1.78, 95% CI 1.27-2.50). In stratified analysis, we found a significant interaction by sex (p-interaction=0.04): in males, CI was associated with elevated stroke risk (HR:2.01, 95% CI:1.39-2.91) without a similar risk in females (HR:1.22, 95% CI:0.85-1.75). Interactions by race, age, and educational level were not statistically significant, but effect sizes were qualitatively larger in White participants and individuals with more education. Conclusion: CI is associated with incident stroke independent of shared risk factors, especially in men. This work adds to our understanding of populations at risk for stroke, thus aiding efforts to optimize stroke prevention in at-risk populations.